| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 150, Issue 4 1244-1252, Copyright © 1993 by American Association of Immunologists
ARTICLES |
KL Rock, C Fleischacker and S Gamble
Division of Lymphocyte Biology, Dana Farber Cancer Institute, Boston, MA 02115.
CTL recognize oligopeptides bound to MHC class I molecules. Immunization of animals with antigenic peptides has often failed to stimulate CTL responses. We confirm that immunizations with several peptides, including natural and optimally active antigenic sequences, do not prime cytotoxic immunity in mice. However, immunization with peptides together with human beta 2-microglobulin primes Ag-specific CTL. Priming is observed when animals receive injections either i.v. with ex vivo peptide/beta 2-microglobulin-pulsed cells or s.c. with an admixture of peptide and beta 2-microglobulin. beta 2-Microglobulin promotes the priming of CTL immunity if it is added with peptide, but not if it is added after cells are exposed to peptide. Synthetic peptides and mixtures of peptides from enzymatically cleaved Ag are immunogenic. When a tryptic digest of OVA or the synthetic peptide (OVA258-276) are used as immunogens, the CTL that respond recognize the endogenously processed epitope presented by an OVA-transfected target cell. The peptide + beta 2-microglobulin-primed CTL are CD4-CD8+ and are class I MHC restricted. Using the immunization protocol with beta 2- microglobulin, we have primed CTL responses with peptides from OVA, Sendai virus, and vesicular stomatitis virus. These results may explain previous failures to prime CTL with peptides in vivo and provide a novel approach for developing peptide-based vaccines for viral diseases.
This article has been cited by other articles:
|
|
 |
|
  C. T. Cady, M. Lahn, M. Vollmer, M. Tsuji, S. J. Seo, C. L. Reardon, R. L. O'Brien, and W. K. Born Response of Murine {gamma}{delta} T Cells to the Synthetic Polypeptide Poly-Glu50Tyr50 1 J. Immunol., August 15, 2000; 165(4): 1790 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Uger, S. M. Chan, and B. H. Barber Covalent Linkage to {beta}2-Microglobulin Enhances the MHC Stability and Antigenicity of Suboptimal CTL Epitopes J. Immunol., May 15, 1999; 162(10): 6024 - 6028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baar Clinical Applications of Dendritic Cell Cancer Vaccines Oncologist, April 1, 1999; 4(2): 140 - 144. [Full Text]
|
|
|
|
 |
|
 M. J. Shields, R. Kubota, W. Hodgson, S. Jacobson, W. E. Biddison, and R. K. Ribaudo The Effect of Human beta 2-Microglobulin on Major Histocompatibility Complex I Peptide Loading and the Engineering of a High Affinity Variant. IMPLICATIONS FOR PEPTIDE-BASED VACCINES J. Biol. Chem., October 23, 1998; 273(43): 28010 - 28018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Shields, N. Assefi, W. Hodgson, E. J. Kim, and R. K. Ribaudo Characterization of the Interactions Between MHC Class I Subunits: A Systematic Approach for the Engineering of Higher Affinity Variants of {beta}2-Microglobulin J. Immunol., March 1, 1998; 160(5): 2297 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Uger and B. H. Barber Creating CTL Targets with Epitope-Linked {beta}2-Microglobulin Constructs J. Immunol., February 15, 1998; 160(4): 1598 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Mey-Tal, C. Schechter, and R. Ehrlich Synthesis and Turnover of beta 2-Microglobulin in Ad12-transformed Cells Defective in Assembly and Transport of Class I Major Histocompatibility Complex Molecules J. Biol. Chem., January 3, 1997; 272(1): 353 - 361. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
